Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 4/20 | 0.37 |
| ▸ | MMP1 | P03956 | 3/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 3/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6243813 | 0.86 | ADAM17 (0.40) | ADAM17MMP1S1PR5MAOBKDM1A | |
| SCHEMBL6234707 | 0.84 | S1PR5 (0.43) | ADAM17MMP1S1PR5MAOBKDM1A | |
| SCHEMBL6242329 | 0.82 | S1PR5 (0.41) | ADAM17MMP1S1PR5MAOBKDM1A | |
| SCHEMBL6383056 | 0.81 | S1PR5 (0.40) | ADAM17MMP1S1PR5MAOBKDM1A | |
| SCHEMBL6239560 | 0.81 | S1PR5 (0.40) | ADAM17MMP1S1PR5MAOBKDM1A | |
| SCHEMBL6238755 | 0.81 | S1PR5 (0.40) | ADAM17MMP1S1PR5MAOBKDM1A | |
| SCHEMBL6236505 | 0.79 | MMP1 (0.37) | ADAM17MMP1S1PR5MAOBKDM1A | |
| SCHEMBL6239521 | 0.71 | MMP1 (0.52) | ADAM17MMP1MMP13 | |
| SCHEMBL6238820 | 0.68 | S1PR1 (0.45) | ADAM17MMP1S1PR5MAOBMMP13 | |
| SCHEMBL6243809 | 0.67 | ADAM17 (0.40) | ADAM17MMP1S1PR5MAOBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215549-A1 | TACE inhibitors | MCCLURE KIM F | 2005-09-29 | — | — | US | disclosed |
| EP-1104412-B1 | TACE INHIBITORS | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20030181441-A1 | TACE INHIBITORS | McCLURE Kim (US) | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181441-A1 | TACE INHIBITORS | ADAMTS5, ADAMTS1, MMP2 | ADAM17 22/4885MMP1 18/4885S1PR5 2007/4885 |
| US-20050215549-A1 | TACE inhibitors | ADAMTS5, ADAMTS1, MMP2 | ADAM17 19/4885MMP1 15/4885S1PR5 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.